- Home
- OCS
as 05-09-2025 4:00pm EST
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
| Founded: | 2003 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 689.8M | IPO Year: | N/A |
| Target Price: | $31.50 | AVG Volume (30 days): | 28.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.79 - $23.08 | Next Earning Date: | 05-08-2025 |
| Revenue: | $847,333 | Revenue Growth: | -14.50% |
| Revenue Growth (this year): | 49.27% | Revenue Growth (next year): | 1920.31% |
Latest Oculis Holding AG Ordinary shares News
OCS Breaking Stock News: Dive into OCS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Oculis Reports Q1 2025 Financial Results and Provides Company Update
GlobeNewswire
a day ago
Oculis Reports Q1 Financial Results and Provides Company Update
GlobeNewswire
3 days ago
Oculis to Present at Upcoming May Investor Conferences
GlobeNewswire
9 days ago
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
GlobeNewswire
14 days ago
Oculis Updates Share Capital
GlobeNewswire
23 days ago
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
GlobeNewswire
25 days ago
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
GlobeNewswire
a month ago
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
Compare OCS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCS Oculis Holding AG Ordinary shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.